A protein important for neuron communication has been linked with patient resistance to Alzheimer’s disease and may delay cognitive decline.
Like the cord that connects a landline telephone handset and the receiver, a neuron needs to make a physical connection with other neurons to communicate and transmit signals, which allow people to think and speak.
Now a new study published in the journal Molecular and Cellular Proteomics suggests the protein, called neuritin, may allow people to retain their neuronal connections even when toxic substances that cause Alzheimer’s attempt to break them down.
Alzheimer’s is the most common cause of dementia and according to the World Health Organisation affects more than 55 million worldwide, with nearly 10 million new cases diagnosed every year.
To diagnose it, doctors use mental competency tests, physical and neurological exams, brain imaging, spinal fluid tests and medical history. Most patients show both a cognitive decline as well as toxic protein accumulation in the brain, which causes neuron death and brain shrinkage.
These abnormal protein aggregates, called amyloid beta plaques and tau tangles, can disrupt neuronal connections and communication, which leads to memory loss and confusion, the hallmark symptoms of Alzheimer’s.
However, while some patients show characteristic signs of Alzheimer’s pathology in their brains they remain mentally competent. These individuals are known as ‘cognitivedly resilient’ by the researchers who conducted the study.
Jeremy Herskowitz, associate professor of neurology at the University of Alabama at Birmingham School of Medicine in the United States, and co-supervisor of the project, said: “How cognitively normal older individuals with Alzheimer’s disease pathology withstand dementia onset is one of the most pivotal, unanswered questions in the field.”
To tackle this question, Dr Herskowitz and Nicholas Seyfried, a professor of biochemistry at Emory University School of Medicine in Atlanta, Georgia, and co-supervisor of the project, teamed up and combined their specialties in proteomics and basic neurology to examine proteins in human brain tissues.
Unlike widely employed hypothesis-driven research, this team studies diseased humans and their tissues first to discover potential therapeutics.
Dr Herskowitz explained: “That’s quite different than traditional approaches, which try to make discoveries in experimental model systems. Our research collectively identifies differences in humans first. Then, after that discovery is made, we can ask questions in experimental model systems to work out what’s going on at the molecular and cellular level.”
The researchers conducted a large mass spectrometry screen of the proteins found in the brains of healthy people, typical Alzheimer’s suferers and cognitively resilient patients. Cheyenne Hurst, a graduate student at Emory and co-lead author on the study, used high-powered computer programming to determine that neuritin correlates with intact cognitive function over time.
“The higher the amount of neuritin you have in your brain, the more likely you are to be cognitively intact,” Ms Hurst said.
The researchers then wanted to test how the protein affects how neurons communicate. To do this, they isolated neurons from the hippocampus of rats and treated them with either neuritin, the pathogenic amyloid beta, or both.
Derian Pugh, a graduate student at UAB and co-lead author, noticed structural differences in the three groups.
But the structure of the neurons exposed to pathogenic amyloid beta was disrupted — and so were their connections with other neurons. He said they “looked like a tree with no branches.”
However, neuritin completely blocked the detrimental effects of amyloid beta on the neuron cultures.
“With these experiments, we were able to recapitulate what happens in humans that display cognitive resilience and a possible mechanism,” Dr Herskowitz said.
The team plans to focus on the basic biology of neuritin but also on how they can harness it as a biomarker of Alzheimer’s or a therapeutic.
Dr Seyfried said: “The ability to estimate the amount of amyloid beta pathology in an older person’s brain using biomarkers is getting very advanced. We can predict quite accurately the presence of amyloid beta in someone’s brain while they’re still alive. If they have a large amount of amyloid beta, but they’re still cognitively normal, they may want to one day get treated with neuritin or drugs that boost neuritin levels so that those symptoms don’t develop into dementia.”